SAB Biotherapeutics Current Cash

The latest current cash for SABS is $14M as of September 2026. That compares with $29M in the prior-year period — down 50.9% year over year. Investors often review this figure alongside SAB Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SABS's current cash moved from $29M to $14M — a 50.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics's operating scale or balance-sheet position.

A current cash figure of $14M for SABS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SABS's current cash ($14M), review year-over-year change from $29M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.